8WK Stock Overview
A platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Abera Bioscience AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.34 |
| 52 Week High | SEK 0.51 |
| 52 Week Low | SEK 0.28 |
| Beta | 1.03 |
| 1 Month Change | 2.43% |
| 3 Month Change | 0.60% |
| 1 Year Change | -13.14% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -70.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8WK | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -9.7% | -3.5% | -2.0% |
| 1Y | -13.1% | -14.7% | 6.9% |
Return vs Industry: 8WK exceeded the German Biotechs industry which returned -14.7% over the past year.
Return vs Market: 8WK underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| 8WK volatility | |
|---|---|
| 8WK Average Weekly Movement | 7.3% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8WK's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 8WK's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 6 | Maria Alriksson | aberabio.com |
Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company’s development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead vaccine candidate is a universal pneumococcal vaccine based on the platform BERA.
Abera Bioscience AB Fundamentals Summary
| 8WK fundamental statistics | |
|---|---|
| Market cap | €6.13m |
| Earnings (TTM) | -€323.42k |
| Revenue (TTM) | €1.10m |
5.6x
P/S Ratio-19.0x
P/E RatioIs 8WK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8WK income statement (TTM) | |
|---|---|
| Revenue | SEK 12.60m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 12.60m |
| Other Expenses | SEK 16.32m |
| Earnings | -SEK 3.72m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 100.00% |
| Net Profit Margin | -29.50% |
| Debt/Equity Ratio | 0% |
How did 8WK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 02:28 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Abera Bioscience AB is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Niklas Elmhammer | Carlsquare AB |
| Herman Kuntscher | Carlsquare AB |